Jonathan Wolleben
Stock Analyst at Citizens
(4.43)
# 330
Out of 5,049 analysts
235
Total ratings
50.86%
Success rate
20.73%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCRX BioCryst Pharmaceuticals | Maintains: Market Outperform | $27 → $25 | $7.17 | +248.68% | 10 | Nov 5, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Outperform | $485 → $527 | $475.87 | +10.74% | 14 | Nov 5, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Market Outperform | $81 → $95 | $70.09 | +35.54% | 12 | Nov 5, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Market Outperform | $20 | $5.00 | +300.00% | 1 | Nov 3, 2025 | |
| SPRB Spruce Biosciences | Upgrades: Market Outperform | $254 | $120.00 | +111.67% | 8 | Oct 28, 2025 | |
| SVRA Savara | Maintains: Market Outperform | $8 → $11 | $4.03 | +172.95% | 9 | Oct 23, 2025 | |
| ATXS Astria Therapeutics | Downgrades: Market Perform | n/a | $12.62 | - | 4 | Oct 15, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Market Outperform | $20 → $29 | $10.81 | +168.27% | 18 | Oct 1, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Market Outperform | $86 → $143 | $42.53 | +236.23% | 16 | Sep 26, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Market Outperform | $135 → $142 | $99.47 | +42.76% | 5 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $27 → $28 | $10.99 | +154.78% | 5 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $3.22 | +459.01% | 13 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $52 | $21.72 | +139.41% | 12 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $9 → $8 | $1.58 | +406.33% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $67 → $69 | $77.88 | -11.40% | 12 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $89 → $87 | $32.21 | +170.10% | 10 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $25 → $15 | $3.75 | +300.00% | 13 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $2.38 | +236.13% | 8 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $14.10 | +48.94% | 15 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $1.51 | +893.38% | 3 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $5.44 | +249.26% | 9 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $75 | $4.07 | +1,742.75% | 11 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $38 | $22.55 | +68.51% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $41.32 | +21.01% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $70.44 | +27.77% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $122.50 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $620.00 | -21.77% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $48 → $32 | $7.77 | +311.84% | 8 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.63 | +1,179.59% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $29.82 | -19.52% | 1 | May 12, 2023 |
BioCryst Pharmaceuticals
Nov 5, 2025
Maintains: Market Outperform
Price Target: $27 → $25
Current: $7.17
Upside: +248.68%
Madrigal Pharmaceuticals
Nov 5, 2025
Maintains: Market Outperform
Price Target: $485 → $527
Current: $475.87
Upside: +10.74%
Mirum Pharmaceuticals
Nov 5, 2025
Maintains: Market Outperform
Price Target: $81 → $95
Current: $70.09
Upside: +35.54%
Kalaris Therapeutics
Nov 3, 2025
Initiates: Market Outperform
Price Target: $20
Current: $5.00
Upside: +300.00%
Spruce Biosciences
Oct 28, 2025
Upgrades: Market Outperform
Price Target: $254
Current: $120.00
Upside: +111.67%
Savara
Oct 23, 2025
Maintains: Market Outperform
Price Target: $8 → $11
Current: $4.03
Upside: +172.95%
Astria Therapeutics
Oct 15, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $12.62
Upside: -
Ocular Therapeutix
Oct 1, 2025
Maintains: Market Outperform
Price Target: $20 → $29
Current: $10.81
Upside: +168.27%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Market Outperform
Price Target: $86 → $143
Current: $42.53
Upside: +236.23%
Rhythm Pharmaceuticals
Sep 25, 2025
Maintains: Market Outperform
Price Target: $135 → $142
Current: $99.47
Upside: +42.76%
Sep 12, 2025
Maintains: Market Outperform
Price Target: $27 → $28
Current: $10.99
Upside: +154.78%
Aug 19, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $3.22
Upside: +459.01%
Aug 13, 2025
Maintains: Market Outperform
Price Target: $55 → $52
Current: $21.72
Upside: +139.41%
Aug 12, 2025
Maintains: Market Outperform
Price Target: $9 → $8
Current: $1.58
Upside: +406.33%
Aug 7, 2025
Maintains: Market Outperform
Price Target: $67 → $69
Current: $77.88
Upside: -11.40%
Aug 7, 2025
Maintains: Market Outperform
Price Target: $89 → $87
Current: $32.21
Upside: +170.10%
Jul 10, 2025
Maintains: Market Outperform
Price Target: $25 → $15
Current: $3.75
Upside: +300.00%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $2.38
Upside: +236.13%
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $21
Current: $14.10
Upside: +48.94%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $1.51
Upside: +893.38%
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $5.44
Upside: +249.26%
May 16, 2025
Reiterates: Market Outperform
Price Target: $75
Current: $4.07
Upside: +1,742.75%
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $22.55
Upside: +68.51%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $41.32
Upside: +21.01%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $70.44
Upside: +27.77%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $122.50
Upside: -
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $620.00
Upside: -21.77%
Aug 15, 2024
Maintains: Market Outperform
Price Target: $48 → $32
Current: $7.77
Upside: +311.84%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.63
Upside: +1,179.59%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $29.82
Upside: -19.52%